Athersys Stock News

Athersys (ATHX) appoints Daniel A. Camardo as the company''s CEO, effective February 14, 2022.Mr

Company has a robust pipeline in late-stage clinical development largely unknown to investors.

Athersys Inc (ATHX) shares closed 0.3% lower than its previous 52 week low, giving the company a market cap of $232M. The stock is currently down 43.6% year-to-date, down 47.5% over the past 12 months, and down 38.3% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 25.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -254.3% The company's stock price performance over the past 12 months lags the peer average by -273.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Athersys Inc. (NASDAQ:ATHX) traded at $0.98 at close of the session on Tuesday, 12/21/21, made a downward move of -1.59% on its previous days price. Looking at the stock we see that its previous close was $1.00 and the beta (5Y monthly) reads -1.58 with the days price range being $0.9663 $1.01. In terms Athersys Inc.s Stock Price Soared Recently, But There Might Be Trouble Ahead Read More »

Analysts expect that Athersys, Inc. (NASDAQ:ATHX) will post earnings of ($0.07) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Athersys earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.05). Athersys reported earnings of ($0.11) per share during the same quarter last year, which suggests a []

Athersys, Inc. (NASDAQ:ATHX) with the stream of 4.00% also noticed, India ECMOHO Limited (NASDAQ:MOHO) encountered a rapid change of -0.30% in the last hour of Wednesdays trading session. Athersys, Inc. The post Bustling Stock: Athersys, Inc. (NASDAQ:ATHX), ECMOHO Limited (NASDAQ:MOHO) appeared first on Stocks Equity .

Sequoia Financial Advisors LLC raised its position in Athersys, Inc. (NASDAQ:ATHX) by 28.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 181,000 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 shares during the period. Sequoia Financial Advisors LLC owned approximately 0.08% of Athersys worth […]

Zacks Investment Research downgraded shares of Athersys (NASDAQ:ATHX) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily []

Zacks Investment Research cut shares of Athersys (NASDAQ:ATHX) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs []

Millennium Management LLC bought a new position in shares of Athersys, Inc. (NASDAQ:ATHX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,002,826 shares of the biopharmaceutical companys stock, valued at approximately $1,444,000. Millennium Management LLC owned approximately 0.44% of Athersys as of []

In the latest trading session, 0.61 million Athersys Inc. (NASDAQ:ATHX) shares changed hands as the companys beta touched -1.57. With the companys most recent per share price at $1.07 changing hands around $0.05 or 4.41% at last look, the market valuation stands at $253.91M. ATHXs current price is a discount, trading about -183.18% off its Athersys Inc. (ATHX): Why Is Stock So Good? Read More »

Athersys (NASDAQ:ATHX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Friday, Zacks.com reports. The firm presently has a $1.25 price objective on the biopharmaceutical companys stock. Zacks Investment Researchs price objective would suggest a potential upside of 21.36% from the companys current price. []

Wall Street brokerages expect Athersys, Inc. (NASDAQ:ATHX) to post ($0.07) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Athersys earnings, with estimates ranging from ($0.09) to ($0.05). Athersys reported earnings per share of ($0.11) in the same quarter last year, which suggests a positive []

Athersys Inc (NASDAQ: ATHX ) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal , Intensive Care Medicine. MUST-ARDS Phase 1/2 trial evaluated the safety and efficacy of MultiStem (invimestrocel) cell therapy in patients with acute respiratory distress syndrome (ARDS). MultiStem treatment was well-tolerated, with no allergic or serious adverse Full story available on Benzinga.com